Ibrutinib-associated atrial fibrillation treatment with catheter ablation

by Ridhima Kapoor, MD, Muhammad Fazal, MD, Paul Cheng, MD, Ronald Witteles, MD, June-Wha Rhee, MD, Tina Baykaner, MD, MPH
Published 2021

Ibrutinib does not prevent kidney fibrosis following acute and chronic injury

by Julie Belliere, Audrey Casemayou, Eloïse Colliou, Hélène El Hachem, Clément Kounde, Alexis Piedrafita, Guylène Feuillet, Joost P. Schanstra, Stanislas Faguer
Published 2021

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

by Ujjani C, Mato A, Hill BT, Allan JN, Lansigan E, Jacobs R, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M
Published 2020

Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence

by Joanne E. Davis, Chia Sharpe, Kylie Mason, Constantine S. Tam, Rachel M. Koldej, David S. Ritchie
Published 2021

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy

by Dan A. Landau, Clare Sun, Daniel Rosebrock, Sarah E. M. Herman, Joshua Fein, Mariela Sivina, Chingiz Underbayev, Delong Liu, Julia Hoellenriegel, Sarangan Ravichandran, Mohammed Z. H. Farooqui, Wandi Zhang, Carrie Cibulskis, Asaf Zviran, Donna S. Neuberg, Dimitri Livitz, Ivana Bozic, Ignaty Leshchiner, Gad Getz, Jan A. Burger, Adrian Wiestner, Catherine J. Wu
Published 2017

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma

by Xiaohong Zhao, Tint Lwin, Ariosto Silva, Bijal Shah, Jiangchuan Tao, Bin Fang, Liang Zhang, Kai Fu, Chengfeng Bi, Jiannong Li, Huijuan Jiang, Mark B. Meads, Timothy Jacobson, Maria Silva, Allison Distler, Lancia Darville, Ling Zhang, Ying Han, Dmitri Rebatchouk, Maurizio Di Liberto, Lynn C. Moscinski, John M. Koomen, William S. Dalton, Kenneth H. Shain, Michael Wang, Eduardo Sotomayor, Jianguo Tao
Published 2017

Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis

by Jari M. Tuomi, Loryn J. Bohne, Tristan W. Dorey, Hailey J. Jansen, Yingjie Liu, Douglas L. Jones, Robert A. Rose
Published 2021

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL

by André F. Rendeiro, Thomas Krausgruber, Nikolaus Fortelny, Fangwen Zhao, Thomas Penz, Matthias Farlik, Linda C. Schuster, Amelie Nemc, Szabolcs Tasnády, Marienn Réti, Zoltán Mátrai, Donát Alpár, Csaba Bödör, Christian Schmidl, Christoph Bock
Published 2020

Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia

by Federica Frezzato, Andrea Visentin, Filippo Severin, Serena Pizzo, Edoardo Ruggeri, Nayla Mouawad, Leonardo Martinello, Elisa Pagnin, Valentina Trimarco, Alessia Tonini, Samuela Carraro, Stefano Pravato, Silvia Imbergamo, Sabrina Manni, Francesco Piazza, Anna Maria Brunati, Monica Facco, Livio Trentin
Published 2021

Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib

by Juan Carlo Avalon, Jacob Fuqua, Tyler Miller, Seth Deskins, Chelby Wakefield, Austin King, Sonya Inderbitzin-Brooks, Christopher Bianco, Lauren Veltri, Wei Fang, Michael Craig, Abraham Kanate, Kelly Ross, Midhun Malla, Brijesh Patel
Published 2021

Ibrutinib for treatment of autoimmune cytopenia after hematopoietic stem cell transplantation: report of 2 cases and literature review

by WEI Ruowen, CHEN Wenlan, XIE Rong, XIA Linghui, YOU Yong
Published 2021

ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia

by Tatiana E. Bialik, Vladimir I. Vorob'ev, Valerii A. Ionin, Loic Ysebaert, Kamil D. Kaplanov, Larisa P. Mendeleeva, Evgenii A. Nikitin, Vadim V. Ptushkin, Olga S. Samoilova, Elena A. Stadnik
Published 2021

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors

by C. I. Edvard Smith, Jennifer R. Brown, Rula Zain, Rula Zain
Published 2021

Waldenström macroglobulinemia: biology, genetics, and therapy

by Paludo J, Ansell SM
Published 2016

Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia

by Leigh Naylor-Adamson, Anisha R. Chacko, Zoe Booth, Stefano Caserta, Jenna Jarvis, Sujoy Khan, Simon P. Hart, Francisco Rivero, David J. Allsup, David J. Allsup, Mònica Arman
Published 2021

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

by Susan M. O’Brien, Jennifer R. Brown, John C. Byrd, Richard R. Furman, Paolo Ghia, Jeff P. Sharman, William G. Wierda
Published 2021

Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission

by Seegobin K, Alhaj Moustafa M, Jiang L, Tun HW
Published 2021

Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis

by Xuelin Feng, Xuelin Feng, Zubiao Song, Mengli Wu, Yanmei Liu, Sushan Luo, Chongbo Zhao, Weixi Zhang
Published 2021

Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence

by Andrei A. Petrenko, Maria I. Kislova, Elena A. Dmitrieva, Eugene A. Nikitin
Published 2021

Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies

by Isha Kapoor, Juraj Bodo, Brian T. Hill, Alexandru Almasan
Published 2021